|
Snapshot
  • A 59-year-old woman with recently diagnosed metastatic estrogen-receptor (ER) positive and human epidermal growth factor 2 (HER2) negative breast cancer presents for follow-up care. She is hormone therapy naive and has non-visceral involvement of the cancer. She is started on letrozole.
Introduction
  • Mechanism of action
    • inhibits peripheral conversion of androgens to estrogens via aromatase inhibition
  • Clinical use
    • estrogen-receptor positive breast cancer
  • Toxicity
    • menopausal symptoms
    • fatigue
  • Medications
    • letrozole
    • anastrozole
    • exemestane
 

Please rate topic.

Average 5.0 of 1 Ratings

EVIDENCE & REFERENCES (1)
Topic COMMENTS (7)
Private Note